Ieq Capital LLC Has $6.79 Million Stock Position in Medpace Holdings, Inc. $MEDP

Key Points

• Ieq Capital LLC has decreased its stake in Medpace Holdings, Inc. by 18.1% during the first quarter, owning approximately 0.08% of Medpace worth around $6.79 million after selling 4,922 shares.
• Medpace reported a 14.2% increase in quarterly revenue year-over-year, with earnings per share of $3.10, exceeding analysts' consensus estimates.
• Analysts currently have a consensus rating of "Reduce" on Medpace stock, with an average target price of $406.60, reflecting a mix of ratings among investment analysts.

Ieq Capital LLC decreased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 18.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,284 shares of the company's stock after selling 4,922 shares during the period. Ieq Capital LLC owned approximately 0.08% of Medpace worth $6,790,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of MEDP. MML Investors Services LLC grew its stake in shares of Medpace by 28.6% in the fourth quarter. MML Investors Services LLC now owns 4,164 shares of the company's stock worth $1,383,000 after acquiring an additional 927 shares during the last quarter. Beacon Pointe Advisors LLC boosted its stake in Medpace by 11.5% during the fourth quarter. Beacon Pointe Advisors LLC now owns 7,608 shares of the company's stock worth $2,528,000 after buying an additional 787 shares in the last quarter. Northern Trust Corp boosted its stake in Medpace by 13.2% during the fourth quarter. Northern Trust Corp now owns 248,142 shares of the company's stock worth $82,440,000 after buying an additional 28,968 shares in the last quarter. Consolidated Press International Holdings Ltd. boosted its stake in Medpace by 8.8% during the fourth quarter. Consolidated Press International Holdings Ltd. now owns 3,700 shares of the company's stock worth $1,229,000 after buying an additional 300 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec boosted its stake in Medpace by 149.9% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 174,569 shares of the company's stock worth $57,997,000 after buying an additional 104,705 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Up 0.5%

Shares of Medpace stock traded up $2.57 during trading on Friday, reaching $475.51. The company's stock had a trading volume of 408,536 shares, compared to its average volume of 336,278. The stock has a 50-day moving average price of $395.75 and a two-hundred day moving average price of $339.36. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $501.30. The stock has a market capitalization of $13.36 billion, a P/E ratio of 35.35, a price-to-earnings-growth ratio of 2.99 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. During the same period in the previous year, the business posted $2.75 earnings per share. The firm's revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Stephen P. Ewald sold 3,000 shares of Medpace stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the transaction, the general counsel directly owned 10,343 shares of the company's stock, valued at $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of the business's stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer owned 6,000 shares of the company's stock, valued at $2,725,380. The trade was a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 115,070 shares of company stock valued at $52,085,751 over the last three months. Company insiders own 20.30% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Mizuho lifted their price target on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Truist Financial lifted their price target on shares of Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and lifted their price target for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Robert W. Baird lifted their price target on shares of Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Finally, Cowen downgraded shares of Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Reduce" and an average target price of $406.60.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.